Anavex Life Sciences Corp. AVXL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -145.16% | -12.55% | -32.42% | 33.61% | 61.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -147.24% | -48.00% | -48.79% | -20.19% | 1.81% |
| Operating Income | 147.24% | 48.00% | 48.79% | 20.19% | -1.81% |
| Income Before Tax | 159.08% | 52.32% | 53.24% | 15.43% | -8.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 159.08% | 52.32% | 53.09% | 15.43% | -8.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 159.08% | 52.32% | 53.09% | 15.43% | -8.42% |
| EBIT | 147.24% | 48.00% | 48.79% | 20.19% | -1.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 154.42% | 56.23% | 55.32% | 16.50% | -7.34% |
| Normalized Basic EPS | 154.49% | 56.26% | 55.43% | 16.47% | -7.31% |
| EPS Diluted | 150.00% | 56.23% | 55.32% | 16.50% | -10.73% |
| Normalized Diluted EPS | 154.28% | 56.26% | 55.43% | 16.47% | -7.31% |
| Average Basic Shares Outstanding | 8.57% | 8.94% | 4.98% | 1.30% | 1.00% |
| Average Diluted Shares Outstanding | 8.81% | 8.94% | 4.98% | 1.30% | 1.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |